KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Current Deferred Revenue (2016 - 2017)

Vertex Pharmaceuticals has reported Current Deferred Revenue over the past 9 years, most recently at $5.2 million for Q4 2017.

  • Quarterly results put Current Deferred Revenue at $5.2 million for Q4 2017, down 13.92% from a year ago — trailing twelve months through Dec 2017 was $5.2 million (down 13.92% YoY), and the annual figure for FY2017 was $5.2 million, down 13.92%.
  • Current Deferred Revenue for Q4 2017 was $5.2 million at Vertex Pharmaceuticals, down from $13.0 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for VRTX hit a ceiling of $35.5 million in Q1 2013 and a floor of $5.2 million in Q4 2017.
  • Median Current Deferred Revenue over the past 5 years was $15.4 million (2015), compared with a mean of $17.5 million.
  • Biggest five-year swings in Current Deferred Revenue: plummeted 63.15% in 2016 and later soared 40.62% in 2017.
  • Vertex Pharmaceuticals' Current Deferred Revenue stood at $21.5 million in 2013, then decreased by 18.79% to $17.5 million in 2014, then dropped by 6.71% to $16.3 million in 2015, then plummeted by 63.15% to $6.0 million in 2016, then fell by 13.92% to $5.2 million in 2017.
  • The last three reported values for Current Deferred Revenue were $5.2 million (Q4 2017), $13.0 million (Q3 2017), and $7.3 million (Q2 2017) per Business Quant data.